Literature DB >> 11960076

Losartan-induced hepatic injury.

Fehmi Tabak1, Ali Mert, Resat Ozaras, Mithat Biyikli, Recep Ozturk, Gulsen Ozbay, Hakan Senturk, Yildirim Aktuglu.   

Abstract

Losartan, an angiotensin II receptor antagonist, is widely used for the treatment of hypertension. Clinical experience with this drug has demonstrated that it is safe. Losartan-induced hepatic toxicity is extremely rare. We report a case of severe hepatic toxicity and fibrosis caused by losartan use, and we review four previously reported cases. Drug-induced hepatic injury may be seen during the treatment of hypertension by losartan and the clinician should be aware of this toxicity, especially during the initial phase of treatment.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11960076     DOI: 10.1097/00004836-200205000-00022

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  8 in total

Review 1.  Clinical pharmacokinetics of losartan.

Authors:  Domenic A Sica; Todd W B Gehr; Siddhartha Ghosh
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Azathioprine induced cholestatic hepatitis.

Authors:  Viju Moses; Banumathi Ramakrishna; Kurien Thomas
Journal:  Indian J Pharmacol       Date:  2011-11       Impact factor: 1.200

3.  Losartan-induced Ischemic Hepatocellular Hepatotoxicity: A Case Report and Literature Review.

Authors:  Moh'd Z Al-Halawani; Mohammad Thawabi; Fady Asslo; Hamid Shaaban; Fayez Shamoon; Walid J Baddoura
Journal:  J Family Med Prim Care       Date:  2014-07

4.  Drug-Induced Liver Injury Due To Losartan.

Authors:  Joana Diogo; Rita Monteiro; Carolina Coelho; Angela Ghiletchi; Rodrigo Leão; Conceição Loureiro
Journal:  Eur J Case Rep Intern Med       Date:  2021-11-25

5.  Drug-Induced Liver Injury From Sacubitril-Valsartan Versus a Single Dose of Acarbose.

Authors:  Supraja Achuthanandan; Amit Dhaliwal; Ravikaran Patti
Journal:  Cureus       Date:  2022-07-19

6.  Angiotensin II protects primary rat hepatocytes against bile salt-induced apoptosis.

Authors:  Golnar Karimian; Manon Buist-Homan; Bojana Mikus; Robert H Henning; Klaas Nico Faber; Han Moshage
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

7.  Fimasartan-induced liver injury in a patient with no adverse reactions on other types of angiotensin II receptor blockers: A case report.

Authors:  Dae Hwa Park; Gee Young Yun; Hyuk Soo Eun; Jong Seok Joo; Ju Seok Kim; Sun Hyung Kang; Hee Seok Moon; Eaum Seok Lee; Byung Seok Lee; Kyung Hee Kim; Seok Hyun Kim
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

8.  Long-Term Safety of a Novel Angiotensin Receptor Blocker, Fimasartan, According to the Absence or Presence of Underlying Liver Disease in Korean Hypertensive Patients: A Prospective, 12-Month, Observational Study.

Authors:  Gyu Chul Oh; Kwon Wook Joo; Myung-A Kim; Dong-Ju Choi; Yoon Jun Kim; Hae-Young Lee
Journal:  Drug Des Devel Ther       Date:  2020-04-03       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.